ENTYVIO — TAKEDA PHARMS USA, approved 2026-02-25 (BLA761133).
115,704 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.